Clinical Trials
22 trialsNCT07428486 2026-05-07
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05292664 2026-03-12
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT03826992 2026-02-18
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Children's Hospital Medical Center, Cincinnati
Phase 1 Recruiting
NCT06325748 2026-02-12
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
Senti Biosciences
Phase 1 Active not recruiting
NCT01840566 2025-12-03
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03263936 2025-10-16
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT03792256 2025-03-21
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Children's Oncology Group
Phase 1 Completed
NCT01186328 2024-02-01
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT02957032 2023-10-10
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Philogen S.p.A.
Phase 1 Terminated
NCT01614197 2023-07-27
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT05330377 2023-04-25
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
University of Kentucky
Phase 1 Withdrawn
NCT01411267 2022-04-04
AC220 for Children With Relapsed/Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT01861002 2021-06-09
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT03661515 2020-05-20
FLAGINEXOR
PETHEMA Foundation
Phase 1 Completed
NCT03135028 2020-03-06
Japanese AML
Gilead Sciences
Phase 1 Terminated
NCT02954653 2019-11-21
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
Pfizer
Phase 1 Terminated
NCT02652871 2019-11-15
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00928200 2019-02-19
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT01324180 2017-08-07
Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01681537 2016-03-17
Lenalidomide Plus Chemotherapy for AML
Massachusetts General Hospital
Phase 1 Completed
NCT02532192 2016-01-06
A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01321346 2015-11-24
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed